This protocol addresses secondary male hypogonadism in men who also present with erectile dysfunction — a combination that influences the choice and sequence of first-line therapy.
The patient has secondary male hypogonadism alongside erectile dysfunction (difficulty achieving or maintaining an erection). This co-occurrence defines a specific management pathway distinct from hypogonadism without sexual dysfunction.
Management begins with a specific oral pharmacological class used as the first-line intervention for erectile dysfunction in this setting. The full structured regimen — including sequencing and the criteria for escalation — is available via the protocol.
Full algorithm, sequencing logic, and escalation criteria not shown here.In hypogonadal men with erectile dysfunction start with a phosphodiesterase type 5 inhibitor (PDE5I) as first line treatment and add testosterone in case of a poor response to PDE5I treatment.
View source ↗